PDF herunterladen
Exp Clin Endocrinol Diabetes 2023; 131(07/08): 402-408
DOI: 10.1055/a-2048-6213
Review

Improving Detection Rates for Primary Aldosteronism

Renata Libianto
1   Hudson Institute of Medical Research, Clayton, Victoria, Australia
2   Monash Health, Clayton, Victoria
3   Monash University, Clayton, Victoria, Australia
,
Michael Stowasser
4   University of Queensland, Brisbane, Queensland, Australia
,
Grant Russell
3   Monash University, Clayton, Victoria, Australia
,
Peter J Fuller
1   Hudson Institute of Medical Research, Clayton, Victoria, Australia
2   Monash Health, Clayton, Victoria
,
Jun Yang
1   Hudson Institute of Medical Research, Clayton, Victoria, Australia
2   Monash Health, Clayton, Victoria
3   Monash University, Clayton, Victoria, Australia
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Primary aldosteronism (PA), once considered a rare disease, is being increasingly recognized as an important cause of hypertension. It is associated with higher rates of cardiovascular complications compared to blood pressure-matched essential hypertension. Targeted treatments are available which can mitigate the excess cardiovascular risks and, in some cases, cure hypertension. Making a timely diagnosis of PA is, therefore, highly beneficial for patients. Furthermore, numerous studies from different parts of the world have found PA to be a relatively common disease that can affect patients in any stage of hypertension, regardless of their age or potassium levels. Despite this well-established data, the current rate of PA detection is appallingly low, much below its actual prevalence. This review explores the challenges that clinicians often face in diagnosing PA and offers strategies that may improve the detection of this potentially curable form of hypertension.

Key words

Hypertension - Cardiovascular incidences - Cardiovascular risk management - Cardiovascular incidences - Hormones


Publikationsverlauf

Eingereicht: 30. Dezember 2022
Eingereicht: 13. Februar 2023

Angenommen: 26. Februar 2023

Artikel online veröffentlicht:
09. Mai 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol 2016; 101: 1889-1916
    CrossrefPubMedGoogle Scholar
  • 2 Milliez P, Girerd X, Plouin PF. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. JACC 2005; 45: 1243-1248
    CrossrefPubMedGoogle Scholar
  • 3 Mulatero P, Monticone S, Bertello C. et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol 2013; 98: 4826-4833
    CrossrefPubMedGoogle Scholar
  • 4 Monticone S, D'Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
    CrossrefPubMedGoogle Scholar
  • 5 Catena C, Colussi G, Lapenna R. et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918
    CrossrefPubMedGoogle Scholar
  • 6 Catena C, Colussi G, Nadalini E. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
    CrossrefPubMedGoogle Scholar
  • 7 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59
    CrossrefPubMedGoogle Scholar
  • 8 Hundemer GL, Imsirovic H, Vaidya A. et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study. Hypertension 2022; 79: 178-186
    CrossrefPubMedGoogle Scholar
  • 9 Cohen JB, Cohen DL, Herman DS. et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med 2020; 174: 289-297
    CrossrefPubMedGoogle Scholar
  • 10 Libianto R, Fuller PJ, Young MJ. et al. Primary aldosteronism is a public health issue: challenges and opportunities. J Hum Hypertens 2020; 34: 478-586
    CrossrefPubMedGoogle Scholar
  • 11 Conn JW.. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
    PubMedGoogle Scholar
  • 12 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. JACC 2017; 69: 1811-1820
    CrossrefPubMedGoogle Scholar
  • 13 Xu Z, Yang J, Hu J. et al. Primary aldosteronism in patients in China with recently detected hypertension. JACC 2020; 75: 1913-1922
    CrossrefPubMedGoogle Scholar
  • 14 Libianto R, Russell GM, Stowasser M. et al. Detecting primary aldosteronism in Australian primary care: A prospective study. Med J Aust 2022; 216: 408-412
    CrossrefPubMedGoogle Scholar
  • 15 Fogari R, Preti P, Zoppi A. et al. Prevalence of primary aldosteronism among unselected hypertensive patients: A prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test. Hypertens Res 2007; 30: 111-117
    CrossrefPubMedGoogle Scholar
  • 16 Kayser SC, Deinum J, de Grauw WJ. et al. Prevalence of primary aldosteronism in primary care: A cross-sectional study. Br J Gen Pract 2018; 68: e114-e122
    CrossrefPubMedGoogle Scholar
  • 17 Galati SJ, Cheesman KC, Springer-Miller R. et al. Prevalence of primary aldosteronism in an urban hypertensive population. Endocr Pract 2016; 22: 1296-1302
    CrossrefPubMedGoogle Scholar
  • 18 Volpe C, Wahrenberg H, Hamberger B. et al. Screening for primary aldosteronism in a primary care unit. JRAAS 2013; 14: 212-219
    PubMedGoogle Scholar
  • 19 Ito Y, Takeda R, Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102
    CrossrefPubMedGoogle Scholar
  • 20 Westerdahl C, Bergenfelz A, Isaksson A. et al. Primary aldosteronism among newly diagnosed and untreated hypertensive patients in a Swedish primary care area. Scan J Prim Health Care 2011; 29: 57-62
    PubMedGoogle Scholar
  • 21 Williams JS, Williams GH, Raji A. et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens 2006; 20: 129-136
    CrossrefPubMedGoogle Scholar
  • 22 Westerdahl C, Bergenfelz A, Isaksson A. et al. High frequency of primary hyperaldosteronism among hypertensive patients from a primary care area in Sweden. Scan J Prim Health Care 2006; 24: 154-159
    CrossrefPubMedGoogle Scholar
  • 23 Schwartz GL, Turner ST.. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-394
    CrossrefPubMedGoogle Scholar
  • 24 Loh KC, Koay ES, Khaw MC. et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol 2000; 85: 2854-2859
    PubMedGoogle Scholar
  • 25 Mosso L, Carvajal C, Gonzalez A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165
    CrossrefPubMedGoogle Scholar
  • 26 Gordon RD, Ziesak MD, Tunny TJ. et al. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296-298
    CrossrefPubMedGoogle Scholar
  • 27 Ma L, Song Y, Mei M. et al. Age-related cutoffs of plasma aldosterone/renin concentration for primary aldosteronism screening. Int J Endocrinol 2018; 2018: 8647026
    PubMedGoogle Scholar
  • 28 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
    CrossrefPubMedGoogle Scholar
  • 29 Funder JW. Primary aldosteronism: Where are we now? Where to from here?. Horm Metab Res 2020; 52: 459-466
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 30 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism. Ann Intern Med. 2020
    PubMedGoogle Scholar
  • 31 Kayser SC, Dekkers T, Groenewoud HJ. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression Analysis. J Clin Endocrinol 2016; 101: 2826-2835
    CrossrefPubMedGoogle Scholar
  • 32 Parasiliti-Caprino M, Lopez C, Prencipe N. et al. Prevalence of primary aldosteronism and association with cardiovascular complications in patients with resistant and refractory hypertension. J Hypertens 2020; 38: 1841-1848
    CrossrefPubMedGoogle Scholar
  • 33 Williams B, MacDonald TM, Morant S. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068
    CrossrefPubMedGoogle Scholar
  • 34 Williams B, MacDonald TM, Morant SV. et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: The PATHWAY-2 mechanisms substudies. Lancet Diab Endocrinol 2018; 6: 464-475
    CrossrefPubMedGoogle Scholar
  • 35 Hu Y, Zhang J, Liu W. et al. Determining the prevalence of primary aldosteronism in patients with new-onset type 2 diabetes and hypertension. J Clin Endocrinol 2020; 105
    PubMedGoogle Scholar
  • 36 Seccia TM, Letizia C, Muiesan ML. et al. Atrial fibrillation as presenting sign of primary aldosteronism: Results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J Hypertens 2020; 38: 332-339
    CrossrefPubMedGoogle Scholar
  • 37 Mulatero P, Monticone S, Burrello J. et al. Guidelines for primary aldosteronism: Uptake by primary care physicians in Europe. J Hypertens 2016; 34: 2253-2257
    CrossrefPubMedGoogle Scholar
  • 38 Rossi E, Perazzoli F, Negro A. et al. Diagnostic rate of primary aldosteronism in Emilia-Romagna, Northern Italy, during 16 years (2000-2015). J Hypertens 2017; 35 1691-1697
    PubMedGoogle Scholar
  • 39 Yang J, Fuller PJ, Stowasser M.. Is it time to screen all patients with hypertension for primary aldosteronism?. Med J Aust 2018; 209: 57-59
    CrossrefPubMedGoogle Scholar
  • 40 Liu YY, King J, Kline GA. et al. Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA Surg. 2021
    PubMedGoogle Scholar
  • 41 Tan SJ, Libianto R, Yang J. et al. Screening for primary aldosteronism in the diabetic population: A cohort study. Intern Med J. 2022
    PubMedGoogle Scholar
  • 42 Chauhan K, Schachna E, Libianto R. et al. Screening for primary aldosteronism is underutilised in patients with chronic kidney disease. J Nephrol. 2022
    PubMedGoogle Scholar
  • 43 Lim YY, Shen J, Fuller PJ. et al. Current pattern of primary aldosteronism diagnosis: Delayed and complicated. Aust J Gen Pract 2018; 47: 712-718
    CrossrefPubMedGoogle Scholar
  • 44 Jaffe G, Gray Z, Krishnan G. et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75: 650-659
    CrossrefPubMedGoogle Scholar
  • 45 Burrello J, Monticone S, Losano I. et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 2020; 75: 1025-1033
    CrossrefPubMedGoogle Scholar
  • 46 Stowasser M, Ahmed AH, Pimenta E. et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-176
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 47 Suntornlohanakul O, Sakarin S, Kietsiriroje N. et al. Geographical inequality in service utilization for primary aldosteronism screening: Spatial epidemiological study in Southern Thailand. BMC Health Serv Res 2022; 22: 458
    CrossrefPubMedGoogle Scholar
  • 48 Cooke G, Valenti L, Glasziou P. et al. Common general practice presentations and publication frequency. Aust Fam Phys 2013; 42: 65-68
    PubMedGoogle Scholar
  • 49 Nainani AK, Yang J, Peters S. et al. 'I can't understand why others don't screen more': A qualitative study exploring why Australian general practitioners screen for primary aldosteronism. BMJ Open 2022; 12: e061671
    CrossrefPubMedGoogle Scholar
  • 50 Schmiemann G, Gebhardt K, Hummers-Pradier E. et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med 2012; 25: 98-103
    CrossrefPubMedGoogle Scholar
  • 51 Wu J, Tian W, Zhang L. et al. Assessing the quality of guidelines for primary aldosteronism: Which guidelines are worth applying in diverse settings?. J Hypertens 2019; 37: 1500-1512
    CrossrefPubMedGoogle Scholar
  • 52 Funder JW, Carey RM, Fardella C. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol 2008; 93: 3266-3281
    CrossrefPubMedGoogle Scholar
  • 53 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. JACC 2018; 71: e127-e248
    CrossrefPubMedGoogle Scholar
  • 54 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36: 1953-2041
    CrossrefPubMedGoogle Scholar
  • 55 Li N, Huang J, Zheng B. et al. Cost-effectiveness analysis of screening for primary aldosteronism in China. Clin Endocrinol 2021; 95: 414-422
    CrossrefPubMedGoogle Scholar
  • 56 Lim YY, Libianto R, Shen J. et al. Impact of Victoria's first dedicated endocrine hypertension service on the pattern of primary aldosteronism diagnoses. Int Med J 2021; 51: 1255-1261
    CrossrefPubMedGoogle Scholar
  • 57 Funder JW, Carey RM.. Primary aldosteronism: Where are we now? Where to from here?. Hypertension 2022; 79: 726-735
    CrossrefPubMedGoogle Scholar
  • 58 Unger T, Borghi C, Charchar F. et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75: 1334-1357
    CrossrefPubMedGoogle Scholar
  • 59 Choy KW, Fuller PJ, Russell G. et al. Primary aldosteronism. Br Med J 2022; 377: e065250
    CrossrefPubMedGoogle Scholar
  • 60 GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1151-1210
    CrossrefPubMedGoogle Scholar
  • 61 Lim SS, Vos T, Flaxman AD. et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260
    CrossrefPubMedGoogle Scholar